

1

L2 ANSWER 10 OF 11 REGISTRY COPYRIGHT 2008 ACS on STN
RN 582294-23-3 REGISTRY
CN L-Tyrosine, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-asparaginyl-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-lysyl-L-glutamyl-L-valyl-L-alanyl-L-alanyl-L-lysyl-L-lysyl-L-tyrosyl-L-leucyl-L-glutamyl-L-seryl-L-isoleucyl-L-lysyl-L-asparaginyl-L-lysyl-L-arginyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN PACAP 66
CN R3P 66
FS PROTEIN SEQUENCE
SQL 31

SEQ 1 HSDAVFTDNY TRLRKQVAAK KYLOSINKR Y

HITS AT: 1-31

RELATED SEQUENCES AVAILABLE WITH SEQLINK

DR 582294-24-4
MF C167 H269 N51 047
CI MAN
SR CA

LC STN Files: CA, CAPLUS, USPATFULL
DT.CA Caplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PROC (Process); PRP (Properties); USES (Uses)
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); PROC (Process); PRP (Properties); USES (Uses)
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 11 OF 11 REGISTRY COPYRIGHT 2008 ACS on STN

RN 463930-25-8 REGISTRY
CN L-Tyrosinamide, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-asparaginyl-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-lysyl-L-glutamyl-L-valyl-L-alanyl-L-alanyl-L-lysyl-L-lysyl-L-tyrosyl-L-leucyl-L-glutamyl-L-seryl-L-isoleucyl-L-lysyl-L-asparaginyl-L-lysyl-L-arginyl- (CA INDEX NAME)

OTHER NAMES:

CN BAY 55-9837
FS PROTEIN SEQUENCE
SQL 31
NTE modified

type	location	description
terminal mod.	Tyr-31	C-terminal amide

SEQ 1 HSDAVFTDNY TRLRKQVAAK KYLOSINKR Y

HITS AT: 1-31

RELATED SEQUENCES AVAILABLE WITH SEQLINK

DR 787278-78-8
MF Unspecified
CI MAN
SR CA

LC STN Files: CA, CAPLUS, CHEMCATS, TOXCENTER
DT.CA Caplus document type: Journal
RL.NP Roles from non-patents: BIOL (Biological study); USES (Uses)
4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

OTHER NAMES:
CN 2: PN: US20050043237 SEQID: 72 claimed protein
FS PROTEIN SEQUENCE
SQL 31

PATENT ANNOTATIONS (PNTE):

Sequence |Patent
Source |Reference
Not Given|US20050043237
|claimed SEQID
|72

SEQ 1 HSDAVFTDNY TRLRKQVAAK KYLOSINKR Y

HITS AT: 1-31

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
CI MAN
SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA Caplus document type: Patent
RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 9 OF 11 REGISTRY COPYRIGHT 2008 ACS on STN

RN 821917-89-9 REGISTRY
CN L-Tyrosine, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-asparaginyl-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-lysyl-L-glutamyl-L-valyl-L-alanyl-L-alanyl-L-lysyl-L-lysyl-L-tyrosyl-L-leucyl-L-glutamyl-L-seryl-L-isoleucyl-L-lysyl-L-asparaginyl-L-lysyl-L-arginyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 74: PN: WO2005000360 SEQID: 72 unclaimed sequence
FS PROTEIN SEQUENCE
SQL 31

PATENT ANNOTATIONS (PNTE):

Sequence |Patent
Source |Reference
Not Given|WO2005000360
|unclaimed
|SEQID 72

SEQ 1 HSDAVFTDNY TRLRKQVAAK KYLOSINKR Y

HITS AT: 1-31

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
CI MAN
SR CA

LC STN Files: CA, CAPLUS, USPATFULL
DT.CA Caplus document type: Patent
RL.P Roles from patents: PRP (Properties)
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

CA 2584095 A1 20060420 CA 2005-2584095 20051007
WO 2006042152 A2 20060420 WO 2005-US36235 20051007
WO 2006042152 A3 20070518
W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CE, CO, CR, CU, CZ, DE, DK, DM, EA, EP, ES, FI, FR, GB, GR, GU, HK, HM, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KR, KZ, LG, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, VZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GR, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
EP 1804820 A2 20070711 EP 2005-806444 20051007
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU
CN 101056647 A 20071017 CN 2005-80039056 20051007
US 2006234933 A 20061019 US 2006-279238 20060410
IN 2007DN02608 A 20070803 IN 2007-DN2608 20070409
KR 2007067136 A 20070627 KR 2007-708327 20070412
US 2004-617500P P 20041008
US 2005-245499 A2 20051007
WO 2005-US36235 A 20051007
US 2006-279238 A2 20060410
PRIORITY APPL. INFO.:
IT 960340-41-4
RL: PRP (Properties)
(unclaimed sequence; synthetic polypeptide analogs of pituitary adenylate cyclase-activating peptide and vasoactive intestinal polypeptide in pharmaceutical compns.)
RN 960340-41-4 HCAPLUS
CN L-Tyrosine, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-asparaginyl-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-lysyl-L-glutamyl-L-valyl-L-alanyl-L-alanyl-L-lysyl-L-tyrosyl-L-leucyl-L-leucyl-L-glutamyl-L-seryl-L-isoleucyl-L-lysyl-L-asparaginyl-L-lysyl-L-arginyl- (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
L4 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:1099691 HCAPLUS
DOCUMENT NUMBER: 145:432605
TITLE: Preparation of vasoactive intestinal polypeptide analog for use in treating metabolic conditions
INVENTOR(S): Nestor, John
PATENT ASSIGNEE(S): U.S. Pat. Appl. Publ., 69pp., Cont.-in-part of U.S. Ser. No. 245,499.
SOURCE: CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:
PATENT NO. KIND DATE APPLICATION NO. DATE
US 2006234933 A1 20061019 US 2006-279238 20060410
US 2006079456 A1 20060413 US 2005-245499 20051007
AU 2005294125 A1 20050420 CA 2005-294125 20051007
CA 2584095 A1 20060420 CA 2005-2584095 20051007
WO 2006042152 A2 20060420 WO 2005-US36235 20051007
WO 2006042152 A3 20070518

=> file hcaplus
COST IN U.S. DOLLARS
FULL ESTIMATED COST 114.68
SINCE FILE ENTRY 114.89
TOTAL SESSION 114.89
FILE 'HCAPLUS' ENTERED AT 09:40:00 ON 23 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.
FILE COVERS 1907 - 23 Jan 2008 VOL 148 ISS 4
FILE LAST UPDATED: 22 Jan 2008 (20080122/ED)
New CAS Information Use Policies, enter HELP USAGETERMS for details.
This file contains CAS Registry Numbers for easy and accurate substance identification.
=> s 12 13 L2
L3
=> s 13 and PACAP
2709 PACAP
86 PACAPS
2711 PACAP
(PACAP OR PACAPS)
L4 6 L3 AND PACAP

=> d 14 1-6 ibib, hitstr
L4 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1447573 HCAPLUS
DOCUMENT NUMBER: 148:70630
TITLE: Synthetic polypeptide analogs of pituitary adenylate cyclase-activating peptide and vasoactive intestinal polypeptide in pharmaceutical compositions
INVENTOR(S): Nestor, John
PATENT ASSIGNEE(S): Therapei Pharmaceuticals, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 63pp., Cont.-in-part of U.S. Ser. No. 279,238.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:
PATENT NO. KIND DATE APPLICATION NO. DATE
US 2007293429 A1 20071220 US 2006-539613 20061006
US 2006079456 A1 20060413 US 2005-245499 20051007
AU 2005294125 A1 20060420 AU 2005-294125 20051007

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, FI, GB, GD, GE, GH, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PI, PL, PT, PU, PY, RE, RU, RW, SA, SC, SD, SE, SG, SH, SI, SJ, SK, SL, SM, SN, SO, SR, SS, ST, SU, SV, SW, SZ, TD, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RN: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

EP 1804820 A2 20070711 EP 2005-806444 20051007

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU

CN 101056647 A 20071017 CN 2005-80039056 20051007

WO 2007044591 A2 20070419 WO 2006-US39267 20061006

WO 2007044591 A3 20071129

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GN, GU, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PG, PH, PI, PL, PT, PU, PY, RE, RU, RW, SA, SC, SD, SE, SG, SH, SI, SJ, SK, SL, SM, SN, SO, SR, SS, ST, SU, SV, SW, SZ, TD, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZM, ZW

RN: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

US 2007293429 A1 20071220 US 2006-539613 20061006

IN 2007DNO2608 A 20070803 IN 2007-DN2608 20070409

KR 2007067136 A 20070627 KR 2007-708327 20070412

PRIORITY APPLN. INFO.: US 2004-617500P P 20041008

US 2005-245499 A2 20051007

WO 2005-US36235 A 20051007

US 2006-279238 A 20060410

IT 912857-17-1

RL: PRP (Properties)
(unclaimed protein sequence; preparation of vasoactive intestinal polypeptide analog for use in treating metabolic conditions)

RN 912857-17-1 HCAPLUS

CN L-Tyrosine, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-threonyl-L-threonyl-L-leucyl-L-arginyl-L-lysyl-L-tyrosyl-L-phenylalanyl-L-arganyl-L-leucyl-L-lysyl-L-glutamyl-L-valyl-L-alanyl-L-alanyl-L-lysyl-L-lysyl-L-tyrosyl-L-leucyl-L-glutamyl-L-seryl-L-isoleucyl-L-lysyl-L-asparagyl-L-lysyl-L-arginyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:160814 HCAPLUS

DOCUMENT NUMBER: 142:254621

TITLE: Pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their therapeutic use for type II diabetes and respiratory disease

INVENTOR(S): Pan, Clark; Tsutsumi, Manami; Shansfelt, Armen B.

PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA

SOURCE: U.S. Pat. Appl. Publ., 123 pp., Division of U.S. Ser. No. 671,773.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

US 2005043237 A1 20050224 US 2004-892981 20040715

US 6972319 B1 20051206 US 2000-671773 20000927

PRIORITY APPLN. INFO.: US 2000-671773 A3 20000927

US 1999-240954P P 19990928

US 2000-327556P P 20000615

IT 845840-21-3P

RL: ANT (Analyte); BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)

(PACAP receptor 3 agonist peptide R3P66; pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their therapeutic use for type II diabetes and respiratory disease)

RN 845840-21-3 HCAPLUS

CN L-Tyrosine, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L-leucyl-L-arganyl-L-lysyl-L-glutamyl-L-threonyl-L-arganyl-L-leucyl-L-lysyl-L-tyrosyl-L-leucyl-L-valyl-L-alanyl-L-alanyl-L-lysyl-L-lysyl-L-tyrosyl-L-leucyl-L-glutamyl-L-seryl-L-isoleucyl-L-lysyl-L-asparagyl-L-lysyl-L-arginyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:917654 HCAPLUS

DOCUMENT NUMBER: 141:389078

TITLE: Differential regulation of activity-dependent neuroprotective protein in rat astrocytes by VIP and PACAP

AUTHOR(S): Zusev, Margalit; Gozes, Ilana

CORPORATE SOURCE: Sackler School of Medicine, Department of Clinical Biochemistry, Tel Aviv University, Tel Aviv-Jaffa, 69978, Israel

SOURCE: Regulatory Peptides (2004), 123(1-3), 33-41

CODEN: REPPDY; ISSN: 0167-0115

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

IT 463930-25-8, BAY 55-9837

RL: BSU (Biological study, unclassified); BIOL (Biological study) of activity-dependent neuroprotective protein expression in newborn rat cerebral astrocytes in culture and receptor role therein

RN 463930-25-8 HCAPLUS

CN L-Tyrosinamide, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L-leucyl-L-arganyl-L-lysyl-L-tyrosyl-L-threonyl-L-arganyl-L-leucyl-L-lysyl-L-glutamyl-L-valyl-L-alanyl-L-alanyl-L-lysyl-L-lysyl-L-tyrosyl-L-leucyl-L-glutamyl-L-isoleucyl-L-lysyl-L-asparagyl-L-lysyl-L-arginyl- (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 50

THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:656793 HCAPLUS

DOCUMENT NUMBER: 139:202489

TITLE: Formulation strategies in stabilizing peptides in organic solvents and in dried states

INVENTOR(S): Wang, Wei; Wang, Yu-Chang John; Martin-Moe, Sheryl

PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003068805	A2	20030821	WO 2003-US4790	20030214
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	A3	20040226		
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, CG, CI, CM, GN, GO, GW, ML, MR, NE, SN, TD, TG				
CA 2472956	A1	20030821	CA 2003-2472956	20030214
AU 2003219787	A1	20030904	AU 2003-219787	20030214
EP 1476178	A2	20041117	EP 2003-716061	20030214
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006514914	T	20060518	JP 2003-567931	20030214
US 2005009739	A1	20050113	US 2004-500680	20040701
PRIORITY APPL. INFO.:			US 2002-356915P	P 20020214
			WO 2003-US4790	W 20030214

IT 582294-23-3, PACAP 66 582294-23-3D, analogs
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(formulation strategies in stabilizing peptides in organic solvents and in dried states)

RN 582294-23-3 HCAPLUS
CN L-Tyrosine, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-asparaglyl-L-tyrosyl-L-threonyl-L-arganyl-L-leucyl-L-tyrosyl-L-glutamyl-L-valyl-L-alanyl-L-alanyl-L-lysyl-L-tyrosyl-L-tyrosyl-L-leucyl-L-glutamyl-L-seryl-L-isoleucyl-L-lysyl-L-asparaglyl-L-lysyl-L-arganyl- (9Ci) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 582294-23-3 HCAPLUS
CN L-Tyrosine, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-asparaglyl-L-tyrosyl-L-threonyl-L-arganyl-L-leucyl-L-tyrosyl-L-tyrosyl-L-glutamyl-L-valyl-L-alanyl-L-alanyl-L-lysyl-L-tyrosyl-L-tyrosyl-L-leucyl-L-glutamyl-L-seryl-L-isoleucyl-L-lysyl-L-asparaglyl-L-lysyl-L-arganyl- (9Ci) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002-335562 HCAPLUS
DOCUMENT NUMBER: 137:257484
TITLE:

A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal:
A potential therapy for type 2 diabetes
Tatsumi, Manami; Claus, Thomas H.; Liang, Yin; Li, Yaxin; Yang, Ling; Zhu, Jian; Dela Cruz, Fernando; Peng, Xianbu; Chen, Hongxing; Yung, Stephanie L.; Hamren, Sarah; Livingston, James N.; Pan, Clark Q.

CORPORATE SOURCE: Department of Metabolic Disorders Research, Pharmaceutical Division, Bayer Corporation, West Haven, CT, USA
SOURCE: Diabetes (2002), 51(5), 1453-1460
CODEN: DIAE2Z; ISSN: 0012-1797
PUBLISHER: American Diabetes Association
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 463930-25-8, BAY 55-9837
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(VPAC2 agonist BAY 55-9837 enhances glucose-induced insulin release and glucose disposal)

RN 463930-25-8 HCAPLUS
CN L-Tyrosine, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-asparaglyl-L-tyrosyl-L-threonyl-L-arganyl-L-leucyl-L-tyrosyl-L-glutamyl-L-valyl-L-alanyl-L-alanyl-L-lysyl-L-tyrosyl-L-tyrosyl-L-leucyl-L-glutamyl-L-seryl-L-isoleucyl-L-lysyl-L-asparaglyl-L-lysyl-L-arganyl- (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 09:31:56 ON 23 JAN 2008)

FILE 'REGISTRY' ENTERED AT 09:32:09 ON 23 JAN 2008

L1 40 S HSDAVFTNTRLRKQVAKYLOSINKRY/SQSP

L2 11 S L1 AND SQL=31

FILE 'HCAPLUS' ENTERED AT 09:40:00 ON 23 JAN 2008

L3 13 S L2

L4 6 S L3 AND PACAP

=> d 13 1-13 ibib, hitstr

L3 ANSWER 1 OF 13 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:1447573 HCAPLUS

DOCUMENT NUMBER: 148:70630

TITLE: Synthetic polypeptide analogs of pituitary adenylate cyclase-activating peptide and vasoactive intestinal polypeptide in pharmaceutical compositions

INVENTOR(S): Nestor, John

PATENT ASSIGNEE(S): Therapei Pharmaceuticals, Inc., USA

SOURCE: U.S. Pat. Appl., Publ., 63pp., Cont.-in-part of U.S.

Ser. No. 279,238.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007293429	A1	20071220	US 2006-539613	20061006
US 2006079456	A1	20060413	US 2005-245499	20051007
AU 2005294125	A1	20060420	AU 2005-294125	20051007
CA 2584095	A1	20060420	CA 2005-2584095	20051007
WO 2006042152	A2	20060420	WO 2005-US36235	20051007
WO 2006042152	A3	20070518		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GN, GU, HA, HE, HF, HG, HH, HI, HM, HN, HO, HP, HQ, HR, HS, HT, HU, HV, HW, HX, HY, HZ, IZ, JA, JB, JC, JD, JE, JF, JG, JH, JI, JJ, JK, JL, JM, JN, JO, JP, JQ, JR, JS, JT, JU, JV, JW, JX, JY, JZ, KA, KB, KC, KD, KE, KF, KG, KH, KI, KJ, KK, KL, KM, KN, KO, KP, KQ, KR, KS, KT, KU, KV, KW, KX, KY, KZ, LA, LB, LC, LD, LE, LF, LG, LH, LI, LJ, LK, LM, LN, LO, LP, LQ, LR, LS, LT, LU, LV, LY, MA, MB, MC, MD, ME, MF, MG, MH, MI, MJ, MK, ML, MN, MO, MP, MQ, MR, MS, MT, MU, MV, MW, MX, MY, MZ, NA, NB, NC, ND, NE, NF, NG, NH, NI, NJ, NK, NL, NM, NO, NP, NQ, NR, NS, NT, NU, NV, NW, NX, NY, NZ, OA, OB, OC, OD, OE, OF, OG, OH, OI, OJ, OK, OL, OM, ON, OP, OQ, OR, OS, OT, OU, OV, OW, OX, OY, OZ, PA, PB, PC, PD, PE, PF, PG, PH, PI, PJ, PK, PL, PM, PN, PO, PP, PQ, PR, PS, PT, PU, PV, PW, PX, PY, PZ, QA, QB, QC, QD, QE, QF, QG, QH, QI, QJ, QK, QL, QM, QN, QO, QP, QQ, QR, QS, QT, QU, QV, QW, QX, QY, QZ, RA, RB, RC, RD, RE, RF, RG, RH, RI, RJ, RK, RL, RM, RN, RO, RP, RQ, RS, RT, RU, RV, RW, RX, RY, RZ, SA, SB, SC, SD, SE, SF, SG, SH, SI, SJ, SK, SL, SM, SN, SO, SP, SQ, SR, SS, ST, SU, SV, SW, SX, SY, SZ, TA, TB, TC, TD, TE, TF, TG, TH, TI, TJ, TK, TL, TM, TN, TO, TP, TQ, TR, TS, TT, TU, TV, TW, TX, TY, TZ, UA, UB, UC, UD, UE, UF, UG, UH, UI, UJ, UK, UL, UM, UN, UO, UP, UQ, UR, US, UT, UV, UW, UX, UY, UZ, VA, VB, VC, VD, VE, VF, VG, VH, VI, VJ, VK, VL, VM, VN, VO, VP, VQ, VR, VS, VT, VU, VV, VW, VX, VY, VZ, WA, WB, WC, WD, WE, WF, WG, WH, WI, WJ, WK, WL, WM, WN, WO, WP, WQ, WR, WS, WT, WU, WV, WX, WY, WZ, XA, XB, XC, XD, XE, XF, XG, XH, XI, XJ, XK, XL, XM, XN, XO, XP, XQ, XR, XS, XT, XU, XV, XW, XX, XY, XZ, YA, YB, YC, YD, YE, YF, YG, YH, YI, YJ, YK, YL, YM, YN, YO, YP, YQ, YR, YS, YT, YU, YV, YW, YX, YZ, ZA, ZB, ZC, ZD, ZE, ZF, ZG, ZH, ZI, ZJ, ZK, ZL, ZM, ZN, ZO, ZP, ZQ, ZR, ZS, ZT, ZU, ZV, ZW, ZX, ZY, ZZ

RN: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU

EP 1804820 A2 20070711 EP 2005-806444 20051007

CN 101036647 A 20071017 CN 2005-80039056 20051007

US 2006234933 A 20061019 US 2006-279238 20060410

IN 2007DN02608 A 20070803 IN 2007-DN2608 20070409

KR 2007067136 A 20070627 KR 2007-708327 20070412

PRIORITY APPL. INFO.: US 2004-617500P P 20041008

US 2005-245499 A2 20051007

WO 2005-US36235 A 20051007

US 2006-279238 A2 20060410

IT 960340-41-4

RL: PRP (Properties)
(unclaimed sequence: synthetic polypeptide analogs of pituitary
adenylate cyclase-activating peptide and vasoactive intestinal
polypeptide in pharmaceutical comps.)

RN 960340-41-4 HCAPLUS

CN L-Tyrosine, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-asparaginyl-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-lysyl-L-tyrosyl-L-glutamyl-L-valyl-L-alanyl-L-alanyl-L-lysyl-L-lysyl-L-tyrosyl-L-leucyl-L-glutamyl-L-seryl-L-isoleucyl-L-lysyl-L-asparaginyl-L-lysyl-L-arginyl- (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L3 ANSWER 2 OF 13 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:473906 HCAPLUS

DOCUMENT NUMBER: 147:132997

TITLE: HIV-1 integration is inhibited by stimulation of the VPAC2 neuroendocrine receptor

AUTHOR(S): Bokaei, Payman Baradar; Ma, Xue-Zhong; Sakac, Darinka; Branch, Donald R.

CORPORATE SOURCE: Institute of Medical Science, University of Toronto, Toronto, ON, M5G 2M1, Can.

SOURCE: Virology (2007), 362(1), 38-49

CODEN: VIRELX; ISSN: 0042-6822

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

IT 463930-25-8, BAY 55-9837

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(HIV-1 integration is inhibited by stimulation of VPAC2 neuroendocrine receptor)

RN 463930-25-8 HCAPLUS

CN L-Tyrosinamide, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-asparaginyl-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-lysyl-L-glutamyl-L-valyl-L-alanyl-L-alanyl-L-lysyl-L-lysyl-L-tyrosyl-L-leucyl-L-glutamyl-L-seryl-L-isoleucyl-L-lysyl-L-asparaginyl-L-lysyl-L-arginyl- (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 13 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:161820 HCAPLUS

DOCUMENT NUMBER: 146:394322

TITLE: Engineering novel VPAC2-selective agonists with improved stability and glucose-lowering activity in vivo

AUTHOR(S): Pan, Clark Q.; Li, Fugang; Tom, Irene; Wang, Wei; Dumas, Michael; Froland, Wayne; Yung, Stephanie L.; Li, Yaxin; Rocznia, Steve; Claus, Thomas H.; Wang, Y. John; Whelan, James P.

CORPORATE SOURCE: Biotechnology, Bayer Healthcare, Berkeley, CA, USA

SOURCE: Journal of Pharmacology and Experimental Therapeutics (2007), 320(2), 900-906

CODEN: JPETAB; ISSN: 0022-3565

PUBLISHER: American Society for Pharmacology and Experimental Therapeutics

DOCUMENT TYPE: Journal

LANGUAGE: English

IT 463930-25-8, BAY 55-9837 933804-12-7, AcBAY

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(engineering novel VPAC2-selective agonists with improved stability and glucose-lowering activity in vivo)

RN 463930-25-8 HCAPLUS

CN L-Tyrosinamide, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-asparaginyl-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-lysyl-L-glutamyl-L-valyl-L-alanyl-L-alanyl-L-lysyl-L-lysyl-L-tyrosyl-L-leucyl-L-glutamyl-L-seryl-L-isoleucyl-L-lysyl-L-asparaginyl-L-lysyl-L-arginyl- (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 933804-12-7 HCAPLUS

CN L-Tyrosine, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-asparaginyl-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-lysyl-L-glutamyl-L-valyl-L-alanyl-L-alanyl-L-lysyl-L-lysyl-L-tyrosyl-L-leucyl-L-glutamyl-L-seryl-L-isoleucyl-L-lysyl-L-asparaginyl-L-lysyl-L-arginyl- (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 13 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:1099691 HCAPLUS

DOCUMENT NUMBER: 145:432605

TITLE: Preparation of vasoactive intestinal polypeptide analog for use in treating metabolic conditions

INVENTOR(S): Nestor, John

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 69pp., Cont.-in-part of U.S. Ser. No. 245,499.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006234933	A1	20061019	US 2006-279238	20060410
US 2006079456	A1	20060413	US 2005-245499	20051007

AU 2005294125 AU 2005-294125 20051007
 CA 2584095 CA 2005-2584095 20051007
 WO 2006042152 WO 2005-US36235 20051007
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LC, LR, LS, LT, LU, LV, LY, MA, MD, ME, MG, MK, MM, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, VZ, VC, VN, YU, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU
 EP 1804820 A2 20070711 EP 2005-806444 20051007
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU
 CN 101056647 A 20071017 CN 2005-80039056 20051007
 WO 2007044591 A2 20070419 WO 2006-US39267 20061006
 WO 2007044591 A3 20071129
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LR, LS, LT, LU, LV, LY, MA, MD, ME, MG, MK, MM, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, VZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU
 US 2007293429 A1 20071220 US 2006-539613 20061006
 IN 200702608 A 20070803 IN 2007-DN2608 20070409
 KR 2007067136 A 20070827 KR 2007-708327 20070412
 P 20041008
 US 2005-245499 A2 20051007
 WO 2005-US36235 A 20051007
 US 2006-279238 A 20060410
 IT 912857-17-1
 RL: PRP (Properties)
 (unclaimed protein sequence; preparation of vasoactive intestinal polypeptide analog for use in treating metabolic conditions)
 RN 912857-17-1 HCAPLUS
 CN L-Tyrosine, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-asparaginyl-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-lysyl-L-lysyl-L-glutamyl-L-valyl-L-alanyl-L-alanyl-L-lysyl-L-lysyl-L-tyrosyl-L-leucyl-L-glutamyl-L-seryl-L-isoleucyl-L-lysyl-L-asparaginyl-L-lysyl-L-arginyl- (9CI) (CA INDEX NAME)
 *** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
 L3 ANSWER 5 OF 13 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:195898 HCAPLUS
 DOCUMENT NUMBER: 144:286712
 TITLE: Selective pegylated VPAC2 receptor peptide agonists for treating diabetes
 INVENTOR(S): Bokvist, Bengt Krister; Mayer, John Philip; Zhang, Lianshan; Alsina-Fernandez, Jorge; Vick, Andrew Mark
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 236 pp.

CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:
 PATENT NO. 2006023358
 WO 2006023358
 W: AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LC, LR, LS, LT, LU, LV, LY, MA, MD, ME, MG, MK, MM, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, VZ, VC, VN, YU, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU
 CA 2577010 A1 20060302 CA 2005-2577010 20050811
 EP 1781694 A1 20070509 EP 2005-784310 20050811
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU
 PRIORITY APPLN. INFO.:
 CA 2577010 A1 20060302 CA 2005-2577010 20050811
 EP 1781694 A1 20070509 EP 2005-784310 20050811
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU
 OTHER SOURCE(S):
 IT 878033-66-0
 RL: PRP (Properties)
 (unclaimed sequence; selective pegylated VPAC2 receptor peptide agonists for treating diabetes)
 RN 878033-66-0 HCAPLUS
 CN L-Tyrosine, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-asparaginyl-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-lysyl-L-lysyl-L-glutamyl-L-valyl-L-alanyl-L-alanyl-L-lysyl-L-lysyl-L-tyrosyl-L-leucyl-L-glutamyl-L-seryl-L-isoleucyl-L-lysyl-L-asparaginyl-L-lysyl-L-arginyl- (9CI) (CA INDEX NAME)
 *** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
 REFERENCE COUNT: 5
 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT
 L3 ANSWER 6 OF 13 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:194266 HCAPLUS
 DOCUMENT NUMBER: 144:286711
 TITLE: Selective pegylated VPAC2 receptor peptide agonists for treating diabetes
 INVENTOR(S): Bokvist, Bengt Krister; Mayer, John Philip; Zhang, Lianshan; Alsina-Fernandez, Jorge; Vick, Andrew Mark
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 496 pp.

for diabetes treatment)

RN 870502-90-2 HCAPLUS
CN L-Tyrosine, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-asparaginy-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-lysyl-L-glutamyl-L-valyl-L-alanyl-L-alanyl-L-lysyl-L-lysyl-L-tyrosyl-L-leucyl-L-glutamyl-L-seryl-L-isoleucyl-L-lysyl-L-asparaginy-L-lysyl-L-arginyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 9 OF 13 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:160814 HCAPLUS
DOCUMENT NUMBER: 142:254621
TITLE: Pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their therapeutic use for type II diabetes and respiratory disease
Pan, Clark; Tsutsumi, Mamami; Shanafelt, Armen B. Bayer Pharmaceuticals Corporation, USA
U.S. Pat. Appl. Publ., 123 pp., Division of U.S. Ser. No. 671,773.
CODEN: USXXCO
Patent
English
1

INVENTOR(S):
PATENT ASSIGNEE(S):
SOURCE:
DOCUMENT TYPE:
LANGUAGE:
FAMILY ACC. NUM. COUNT:
PRIORITY APPL. INFO.:
PATENT NO. KIND DATE APPLICATION NO. DATE

US 2005043237 A1 20050224 US 2004-892981 20040715
US 6972319 B1 20051206 US 2000-671773 20000927
US 2000-671773 A3 20000927
US 1999-240954 P 19990928
US 2000-327556 P 20000615

IT 845840-21-3P
RL: ANT (Analyte); BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
[PACAP receptor 3 agonist peptide R3P66; pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their therapeutic use for type II diabetes and respiratory disease]

RN 845840-21-3 HCAPLUS
CN L-Tyrosine, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-asparaginy-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-lysyl-L-lysyl-L-glutamyl-L-valyl-L-alanyl-L-alanyl-L-lysyl-L-lysyl-L-tyrosyl-L-leucyl-L-glutamyl-L-seryl-L-isoleucyl-L-lysyl-L-asparaginy-L-lysyl-L-arginyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L3 ANSWER 10 OF 13 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:14261 HCAPLUS
DOCUMENT NUMBER: 142:114733
TITLE: Polymer derivatives having particular atom arrangements in a linking group, their preparation, and use in compositions and as conjugates
Harris, J. Milton; Kozlowski, Antoni; McKanus, Samuel P.; Bentley, Michael D.; Charles, Stephen A. Nektar Therapeutics AL, Corporation, USA
PCT Int. Appl., 113 pp.
CODEN: PIXXD2
Patent
English

INVENTOR(S):
PATENT ASSIGNEE(S):
SOURCE:
DOCUMENT TYPE:
LANGUAGE:
FAMILY ACC. NUM. COUNT:
PRIORITY APPL. INFO.:
PATENT NO. KIND DATE APPLICATION NO. DATE

US 2005043237 A1 20050224 US 2004-892981 20040715
US 6972319 B1 20051206 US 2000-671773 20000927
US 2000-671773 A3 20000927
US 1999-240954 P 19990928
US 2000-327556 P 20000615

IT 845840-21-3P
RL: ANT (Analyte); BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
[PACAP receptor 3 agonist peptide R3P66; pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their therapeutic use for type II diabetes and respiratory disease]

RN 845840-21-3 HCAPLUS
CN L-Tyrosine, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-asparaginy-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-lysyl-L-lysyl-L-glutamyl-L-valyl-L-alanyl-L-alanyl-L-lysyl-L-lysyl-L-tyrosyl-L-leucyl-L-glutamyl-L-seryl-L-isoleucyl-L-lysyl-L-asparaginy-L-lysyl-L-arginyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L3 ANSWER 11 OF 13 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:917654 HCAPLUS
DOCUMENT NUMBER: 141:389078
TITLE: Differential regulation of activity-dependent neuroprotective protein in rat astrocytes by VIP and PACAP
Zusev, Margalit; Gozes, Ilana Sackler School of Medicine, Department of Clinical Biochemistry, Tel Aviv University, Tel Aviv-Jaffa, 69978, Israel
CODEN: REPPDY; ISSN: 0167-0115
Regulatory Peptides (2004), 123(1-3), 33-41
CODEN: REPPDY; ISSN: 0167-0115
Elsevier B.V.
Journal
English

INVENTOR(S):
PATENT ASSIGNEE(S):
SOURCE:
DOCUMENT TYPE:
LANGUAGE:
FAMILY ACC. NUM. COUNT:
PRIORITY APPL. INFO.:
PATENT NO. KIND DATE APPLICATION NO. DATE

US 2005043237 A1 20050224 US 2004-892981 20040715
US 6972319 B1 20051206 US 2000-671773 20000927
US 2000-671773 A3 20000927
US 1999-240954 P 19990928
US 2000-327556 P 20000615

IT 845840-21-3P
RL: ANT (Analyte); BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
[PACAP receptor 3 agonist peptide R3P66; pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their therapeutic use for type II diabetes and respiratory disease]

RN 845840-21-3 HCAPLUS
CN L-Tyrosine, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-asparaginy-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-lysyl-L-lysyl-L-glutamyl-L-valyl-L-alanyl-L-alanyl-L-lysyl-L-lysyl-L-tyrosyl-L-leucyl-L-glutamyl-L-seryl-L-isoleucyl-L-lysyl-L-asparaginy-L-lysyl-L-arginyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L3 ANSWER 12 OF 13 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:917654 HCAPLUS
DOCUMENT NUMBER: 141:389078
TITLE: Differential regulation of activity-dependent neuroprotective protein in rat astrocytes by VIP and PACAP
Zusev, Margalit; Gozes, Ilana Sackler School of Medicine, Department of Clinical Biochemistry, Tel Aviv University, Tel Aviv-Jaffa, 69978, Israel
CODEN: REPPDY; ISSN: 0167-0115
Regulatory Peptides (2004), 123(1-3), 33-41
CODEN: REPPDY; ISSN: 0167-0115
Elsevier B.V.
Journal
English

INVENTOR(S):
PATENT ASSIGNEE(S):
SOURCE:
DOCUMENT TYPE:
LANGUAGE:
FAMILY ACC. NUM. COUNT:
PRIORITY APPL. INFO.:
PATENT NO. KIND DATE APPLICATION NO. DATE

US 2005043237 A1 20050224 US 2004-892981 20040715
US 6972319 B1 20051206 US 2000-671773 20000927
US 2000-671773 A3 20000927
US 1999-240954 P 19990928
US 2000-327556 P 20000615

IT 845840-21-3P
RL: ANT (Analyte); BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
[PACAP receptor 3 agonist peptide R3P66; pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their therapeutic use for type II diabetes and respiratory disease]

RN 845840-21-3 HCAPLUS
CN L-Tyrosine, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-asparaginy-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-lysyl-L-lysyl-L-glutamyl-L-valyl-L-alanyl-L-alanyl-L-lysyl-L-lysyl-L-tyrosyl-L-leucyl-L-glutamyl-L-seryl-L-isoleucyl-L-lysyl-L-asparaginy-L-lysyl-L-arginyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L3 ANSWER 13 OF 13 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:917654 HCAPLUS
DOCUMENT NUMBER: 141:389078
TITLE: Differential regulation of activity-dependent neuroprotective protein in rat astrocytes by VIP and PACAP
Zusev, Margalit; Gozes, Ilana Sackler School of Medicine, Department of Clinical Biochemistry, Tel Aviv University, Tel Aviv-Jaffa, 69978, Israel
CODEN: REPPDY; ISSN: 0167-0115
Regulatory Peptides (2004), 123(1-3), 33-41
CODEN: REPPDY; ISSN: 0167-0115
Elsevier B.V.
Journal
English

INVENTOR(S):
PATENT ASSIGNEE(S):
SOURCE:
DOCUMENT TYPE:
LANGUAGE:
FAMILY ACC. NUM. COUNT:
PRIORITY APPL. INFO.:
PATENT NO. KIND DATE APPLICATION NO. DATE

US 2005043237 A1 20050224 US 2004-892981 20040715
US 6972319 B1 20051206 US 2000-671773 20000927
US 2000-671773 A3 20000927
US 1999-240954 P 19990928
US 2000-327556 P 20000615

IT 845840-21-3P
RL: ANT (Analyte); BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
[PACAP receptor 3 agonist peptide R3P66; pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their therapeutic use for type II diabetes and respiratory disease]

RN 845840-21-3 HCAPLUS
CN L-Tyrosine, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-asparaginy-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-lysyl-L-lysyl-L-glutamyl-L-valyl-L-alanyl-L-alanyl-L-lysyl-L-lysyl-L-tyrosyl-L-leucyl-L-glutamyl-L-seryl-L-isoleucyl-L-lysyl-L-asparaginy-L-lysyl-L-arginyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L3 ANSWER 14 OF 13 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:917654 HCAPLUS
DOCUMENT NUMBER: 141:389078
TITLE: Differential regulation of activity-dependent neuroprotective protein in rat astro

CN L-Tyrosinamide, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-phenylalaninyl-L-threoninyl-L- α -aspartyl-L-asparaginyl-L-tyrosyl-L-threoninyl-L-argininyl-L-leucyl-L-lysyl-L-glutaminy-L-valyl-L-alanyl-L-alanyl-L-lysyl-L-tyrosyl-L-leucyl-L-glutaminy-L-seryl-L-isoleucyl-L-lysyl-L-asparaginyl-L-lysyl-L-arginyl- (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 12 OF 13 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:656793 HCAPLUS
DOCUMENT NUMBER: 139:202489
TITLE: Formulation strategies in stabilizing peptides in organic solvents and in dried states

INVENTOR(S): Wang, Wei; Wang, Yu-Chang John; Martin-Moe, Sheryl
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003068805	A2	20030821	WO 2003-US4790	20030214
WO 2003068805	A3	20040226		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
R: CH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2472956	A1	20030821	CA 2003-2472956	20030214
AU 2003219787	A1	20030904	AU 2003-219787	20030214
EP 1476178	A2	20041117	EP 2003-716061	20030214
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006514914	T	20060518	JP 2003-567931	20030214
US 2005009739	A1	20050113	US 2004-500680	20040701
PRIORITY APPLN. INFO.: US 2002-356915P P 20020214				
WO 2003-US4790 W 20030214				

IT 582294-23-3, PACAP 66 582294-23-3D, analogs
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(formulation strategies in stabilizing peptides in organic solvents and in dried states)

RN 582294-23-3 HCAPLUS
CN L-Tyrosine, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-phenylalaninyl-L-threoninyl-L- α -aspartyl-L-asparaginyl-L-tyrosyl-L-threoninyl-L-argininyl-L-leucyl-L-lysyl-L-glutaminy-L-valyl-L-alanyl-L-alanyl-L-lysyl-L-tyrosyl-L-leucyl-L-glutaminy-L-seryl-L-isoleucyl-L-lysyl-L-asparaginyl-L-lysyl-L-arginyl- (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 582294-23-3 HCAPLUS
CN L-Tyrosine, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-phenylalaninyl-L-threoninyl-L- α -aspartyl-L-asparaginyl-L-tyrosyl-L-threoninyl-L-argininyl-L-leucyl-L-lysyl-L-glutaminy-L-valyl-L-alanyl-L-alanyl-L-lysyl-L-tyrosyl-L-leucyl-L-glutaminy-L-seryl-L-isoleucyl-L-lysyl-L-asparaginyl-L-lysyl-L-arginyl- (CA INDEX NAME)

threonyl-L-arginyl-L-leucyl-L-arginyl-L-lysyl-L-glutaminy-L-valyl-L-alanyl-L-alanyl-L-lysyl-L-tyrosyl-L-leucyl-L-glutaminy-L-seryl-L-isoleucyl-L-lysyl-L-asparaginyl-L-lysyl-L-arginyl- (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L3 ANSWER 13 OF 13 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:335562 HCAPLUS
DOCUMENT NUMBER: 137:257484
TITLE: A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal:

AUTHOR(S): Tsutsumi, Manami; Claus, Thomas H.; Liang, Yin; Li, Yaxin; Yang, Ling; Zhu, Jian; Dela Cruz, Fernando; Peng, Xianbu; Chen, Hongxing; Yung, Stephanie L.; Hamfen, Sarah; Livingston, James N.; Pan, Clark Q.
CORPORATE SOURCE: Department of Metabolic Disorders Research, Pharmaceutical Division, Bayer Corporation, West Haven, CT, USA

SOURCE: Diabetes (2002), 51(5), 1453-1460

CODEN: DIABEZ; ISSN: 0012-1797

PUBLISHER: American Diabetes Association

DOCUMENT TYPE: Journal

LANGUAGE: English

IT 463930-25-8, BAY 55-9837

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(VPAC2 agonist BAY 55-9837 enhances glucose-induced insulin release and glucose disposal)

RN 463930-25-8 HCAPLUS

CN L-Tyrosinamide, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-phenylalaninyl-L-threoninyl-L- α -aspartyl-L-asparaginyl-L-tyrosyl-L-threoninyl-L-argininyl-L-leucyl-L-lysyl-L-glutaminy-L-valyl-L-alanyl-L-alanyl-L-lysyl-L-tyrosyl-L-leucyl-L-glutaminy-L-seryl-L-isoleucyl-L-lysyl-L-asparaginyl-L-lysyl-L-arginyl- (CA INDEX NAME)